SlideShare a Scribd company logo
Mumps
Dr. Shubhangi S. Kshirsagar
Assistant professor
Department of Swasthavritta & Yoga
Mumps
An acute infectious disease
caused by an RNA virus.
 Clinically, the disease is
recognized by non-
suppurative enlargement
and tenderness of one or
both the parotid glands.
Other organs may also be
involved.
Agent factors
a. Agent - Myxovirus parotiditis is a RNA virus
of the myxovirus family.
b. Source of infection
 Clinical and subclinical cases.
 Subclinical cases - 30-40 per cent of all cases
and responsible for maintaining the cycle of
infection.
c. Period of communicability - 4-6 days before the
onset of symptoms and a week or more
thereafter.
d. Secondary attack rate - 86 per cent.
Host factors
a. Age – 5-9 years of age.
b. Immunity
 One attack, clinical or subclinical, is assumed
to induce lifelong immunity.
 Most infants below the age of 6 months are
immune because of maternal antibodies.
Environmental factors
 Cases occur throughout the year, but the peak
incidence is in winter and spring.
 Epidemics are often associated with
overcrowding.
Mode of transmission
1. Droplet infection
2. Direct contact with an infected person.
Incubation period
Varies from 2 to 4 weeks, usually 14-18 days
Clinical features
Mumps is a generalized virus infection.
 30-40 per cent of cases mumps infection is
clinically non-apparent.
In clinically apparent cases,
 Pain and swelling in either one or both the parotid
glands
 It may also involve the sublingual and
submandibular glands.
 The child complains of ear ache on the affected
side prior to the onset of swelling.
 There may be pain and stiffness on opening
the mouth.
 Mumps may also affect the testes, pancreas,
CNS, ovaries, prostate, etc.
 In severe cases, there may be fever, headache
and other constitutional symptoms which may
last from 3-5 days.
 The swelling subsides slowly over 1-2 weeks.
Complications
Orchitis
Ovaritis
Pancreatitis
Meningoencephalitis
Thyroiditis
Neuritis
Hepatitis
 Myocarditis
Sensorineural deafness
Prevention
Live attenuated vaccine
Widely-used live attenuated mumps vaccine
strains include the JerylLynn, RIT 4385,
Leningrad-3, L-Zagreb and Urabe strains.
Single dose (0.5 ml) intramuscularly produces
detectable antibodies in 95 per cent of vaccines.
First dose – over 1 year of age children, either
alone or in combination(MMR)
Second dose – at 4-6 years of age
Control
 The control of mumps is difficult because the
disease is infectious before a diagnosis can be
made.
 The long and variable incubation period and the
occurrence of subclinical cases make the control
of spread difficult.
 Isolation - Cases should be isolated till the
clinical manifestations subside.
 Disinfection of the articles used by the patient.
 Surveillance - Contacts should be kept under
surveillance.
Thank You !

More Related Content

What's hot

Diphtheria
DiphtheriaDiphtheria
Diphtheria
mtd_n91
 

What's hot (20)

Diptheria
DiptheriaDiptheria
Diptheria
 
Mumps
MumpsMumps
Mumps
 
Pertusis or Whooping cough class presentation
Pertusis or  Whooping cough class presentation Pertusis or  Whooping cough class presentation
Pertusis or Whooping cough class presentation
 
Mumps
Mumps Mumps
Mumps
 
Whooping cough (pertussis)
Whooping cough (pertussis)Whooping cough (pertussis)
Whooping cough (pertussis)
 
Diptheria
DiptheriaDiptheria
Diptheria
 
Chicken pox
Chicken  poxChicken  pox
Chicken pox
 
Diphtheria
DiphtheriaDiphtheria
Diphtheria
 
Pertusis ( Whooping Cough)
Pertusis ( Whooping Cough)Pertusis ( Whooping Cough)
Pertusis ( Whooping Cough)
 
MMR
MMRMMR
MMR
 
Chickenpox
ChickenpoxChickenpox
Chickenpox
 
Rubella (German Measles)
Rubella (German Measles)Rubella (German Measles)
Rubella (German Measles)
 
Yellow fever
Yellow feverYellow fever
Yellow fever
 
Amoebiasis
AmoebiasisAmoebiasis
Amoebiasis
 
Plague
Plague Plague
Plague
 
Chicken pox
Chicken poxChicken pox
Chicken pox
 
Rubella
Rubella  Rubella
Rubella
 
Chicken pox
Chicken poxChicken pox
Chicken pox
 
Chicken pox (varicella)
Chicken pox  (varicella)Chicken pox  (varicella)
Chicken pox (varicella)
 
MEASLES
MEASLESMEASLES
MEASLES
 

Similar to Mumps

Meningococcal meningitis
Meningococcal meningitisMeningococcal meningitis
Meningococcal meningitis
amitakashyap1
 
Congenital Viral Infection
Congenital Viral InfectionCongenital Viral Infection
Congenital Viral Infection
Dang Thanh Tuan
 
6 october -Poliomyelitis -.ppt
6 october -Poliomyelitis -.ppt6 october -Poliomyelitis -.ppt
6 october -Poliomyelitis -.ppt
Drmayuribhise
 

Similar to Mumps (20)

Epidemiology of mumps.pptx. .
Epidemiology of mumps.pptx.              .Epidemiology of mumps.pptx.              .
Epidemiology of mumps.pptx. .
 
Mumps
MumpsMumps
Mumps
 
Measles Full PSM
Measles Full PSMMeasles Full PSM
Measles Full PSM
 
Pertusis
PertusisPertusis
Pertusis
 
Mumps
MumpsMumps
Mumps
 
epidofmeasles-180920162327.pdf
epidofmeasles-180920162327.pdfepidofmeasles-180920162327.pdf
epidofmeasles-180920162327.pdf
 
Epidemiology of measles
Epidemiology of measlesEpidemiology of measles
Epidemiology of measles
 
TORCH INFECTION
TORCH INFECTIONTORCH INFECTION
TORCH INFECTION
 
Meningococcal meningitis
Meningococcal meningitisMeningococcal meningitis
Meningococcal meningitis
 
Rubella+chicken pox
Rubella+chicken poxRubella+chicken pox
Rubella+chicken pox
 
MEASLES - THEORY.ppt
MEASLES - THEORY.pptMEASLES - THEORY.ppt
MEASLES - THEORY.ppt
 
Respiratory infections
Respiratory infectionsRespiratory infections
Respiratory infections
 
Rubella
RubellaRubella
Rubella
 
Infections in pregnancy 1 3 15
Infections in pregnancy 1 3 15Infections in pregnancy 1 3 15
Infections in pregnancy 1 3 15
 
Emerging and reemerging infections.ppt
Emerging and reemerging infections.pptEmerging and reemerging infections.ppt
Emerging and reemerging infections.ppt
 
Congenital Viral Infection
Congenital Viral InfectionCongenital Viral Infection
Congenital Viral Infection
 
Poliomyelitis
Poliomyelitis Poliomyelitis
Poliomyelitis
 
6 october -Poliomyelitis -.ppt
6 october -Poliomyelitis -.ppt6 october -Poliomyelitis -.ppt
6 october -Poliomyelitis -.ppt
 
Vaccine3 polio
Vaccine3 polioVaccine3 polio
Vaccine3 polio
 
communicable disease (3).pptx
communicable disease  (3).pptxcommunicable disease  (3).pptx
communicable disease (3).pptx
 

More from Dr Shubhangi (Kshirsagar) Hedau

More from Dr Shubhangi (Kshirsagar) Hedau (20)

RNTCP programme.pdf
RNTCP programme.pdfRNTCP programme.pdf
RNTCP programme.pdf
 
National Leprosy Eradication programme.pdf
National Leprosy Eradication programme.pdfNational Leprosy Eradication programme.pdf
National Leprosy Eradication programme.pdf
 
World health organisation.pdf
World health organisation.pdfWorld health organisation.pdf
World health organisation.pdf
 
Epidemiology of Cholera
Epidemiology of CholeraEpidemiology of Cholera
Epidemiology of Cholera
 
Typhoid fever
Typhoid feverTyphoid fever
Typhoid fever
 
Lymphatic filariasis
Lymphatic filariasisLymphatic filariasis
Lymphatic filariasis
 
Epidemiology of Malaria
Epidemiology of MalariaEpidemiology of Malaria
Epidemiology of Malaria
 
Severe acute respiratory syndrome (SARS)
Severe acute respiratory syndrome (SARS)Severe acute respiratory syndrome (SARS)
Severe acute respiratory syndrome (SARS)
 
Measles
Measles Measles
Measles
 
Vital statistics health statistics
Vital statistics   health statisticsVital statistics   health statistics
Vital statistics health statistics
 
Epidemiology of chickenpox
Epidemiology of chickenpoxEpidemiology of chickenpox
Epidemiology of chickenpox
 
Epidemiology of tuberculosis
Epidemiology of tuberculosisEpidemiology of tuberculosis
Epidemiology of tuberculosis
 
Concept & levels of prevention
Concept & levels of preventionConcept & levels of prevention
Concept & levels of prevention
 
Immunizing agents vaccines, immunoglobulines and antisera
Immunizing agents   vaccines, immunoglobulines and antiseraImmunizing agents   vaccines, immunoglobulines and antisera
Immunizing agents vaccines, immunoglobulines and antisera
 
Disinfection
DisinfectionDisinfection
Disinfection
 
Modes of intervention
Modes of interventionModes of intervention
Modes of intervention
 
Concpt & levels of prevention
Concpt & levels of preventionConcpt & levels of prevention
Concpt & levels of prevention
 
Immunity host defences
Immunity   host defencesImmunity   host defences
Immunity host defences
 
Epidemiology of leprosy
Epidemiology of leprosyEpidemiology of leprosy
Epidemiology of leprosy
 
Modes of transmission
Modes of transmissionModes of transmission
Modes of transmission
 

Recently uploaded

Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
MedicoseAcademics
 

Recently uploaded (20)

Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
 
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)#  Jaipur #𝕔ALL #𝕘IRLS
𝕔ALL #𝕘IRLS Service in Jaipur %(8901183002)# Jaipur #𝕔ALL #𝕘IRLS
 
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t..."Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
5cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +852975043415cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +85297504341
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...
 
End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 

Mumps

  • 1. Mumps Dr. Shubhangi S. Kshirsagar Assistant professor Department of Swasthavritta & Yoga
  • 2. Mumps An acute infectious disease caused by an RNA virus.  Clinically, the disease is recognized by non- suppurative enlargement and tenderness of one or both the parotid glands. Other organs may also be involved.
  • 3.
  • 4. Agent factors a. Agent - Myxovirus parotiditis is a RNA virus of the myxovirus family. b. Source of infection  Clinical and subclinical cases.  Subclinical cases - 30-40 per cent of all cases and responsible for maintaining the cycle of infection. c. Period of communicability - 4-6 days before the onset of symptoms and a week or more thereafter. d. Secondary attack rate - 86 per cent.
  • 5. Host factors a. Age – 5-9 years of age. b. Immunity  One attack, clinical or subclinical, is assumed to induce lifelong immunity.  Most infants below the age of 6 months are immune because of maternal antibodies.
  • 6. Environmental factors  Cases occur throughout the year, but the peak incidence is in winter and spring.  Epidemics are often associated with overcrowding.
  • 7. Mode of transmission 1. Droplet infection 2. Direct contact with an infected person.
  • 8. Incubation period Varies from 2 to 4 weeks, usually 14-18 days
  • 9. Clinical features Mumps is a generalized virus infection.  30-40 per cent of cases mumps infection is clinically non-apparent. In clinically apparent cases,  Pain and swelling in either one or both the parotid glands  It may also involve the sublingual and submandibular glands.  The child complains of ear ache on the affected side prior to the onset of swelling.
  • 10.  There may be pain and stiffness on opening the mouth.  Mumps may also affect the testes, pancreas, CNS, ovaries, prostate, etc.  In severe cases, there may be fever, headache and other constitutional symptoms which may last from 3-5 days.  The swelling subsides slowly over 1-2 weeks.
  • 12. Prevention Live attenuated vaccine Widely-used live attenuated mumps vaccine strains include the JerylLynn, RIT 4385, Leningrad-3, L-Zagreb and Urabe strains. Single dose (0.5 ml) intramuscularly produces detectable antibodies in 95 per cent of vaccines. First dose – over 1 year of age children, either alone or in combination(MMR) Second dose – at 4-6 years of age
  • 13. Control  The control of mumps is difficult because the disease is infectious before a diagnosis can be made.  The long and variable incubation period and the occurrence of subclinical cases make the control of spread difficult.  Isolation - Cases should be isolated till the clinical manifestations subside.  Disinfection of the articles used by the patient.  Surveillance - Contacts should be kept under surveillance.